Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease

NCT02110953 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT02110953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02110953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
January 29, 2016
Completion date
August 16, 2017
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver metastases, mucinous adenocarcinoma of the colon, mucinous adenocarcinoma of the rectum, recurrent colon cancer, recurrent rectal cancer, signet ring adenocarcinoma of the colon, signet ring adenocarcinoma of the rectum, stage iva colon cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb rectal cancer